News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Shire Pharmaceuticals Group plc Vyvanse Drug Disappointment Hits Shares
April 25, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LONDON, April 25 (Reuters) - Britain's Shire Plc said on Friday that 2008 sales of its biggest drug hope, Vyvanse for attention deficit hyperactivity disorder (ADHD), would be at the lower end of its expectations, hitting its shares.
Twitter
LinkedIn
Facebook
Email
Print
Earnings
Europe
MORE ON THIS TOPIC
C-suite
Sarepta CEO Doug Ingram To Step Down as Muscular Dystrophy Mission Hits Home
February 25, 2026
·
2 min read
·
Annalee Armstrong
Weight loss
Novo Leans Into Oral Route With Weight Loss Partnership Worth up to $2.1B
February 25, 2026
·
2 min read
·
Tristan Manalac
Startups
Harbour Cofunds Cancer Startup, Hands Off Clinical-Stage Antibody
February 25, 2026
·
2 min read
·
Tristan Manalac
Funding
Slate, Alveus Raise Hefty Series A Hauls for Migraine, Obesity Drugs
February 25, 2026
·
2 min read
·
Tristan Manalac